Trials / Completed
CompletedNCT00389896
A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0733 / Duration of Treatment: 18 Weeks | |
| DRUG | Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks |
Timeline
- Start date
- 2001-07-26
- Primary completion
- 2002-10-04
- Completion
- 2002-10-04
- First posted
- 2006-10-19
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00389896. Inclusion in this directory is not an endorsement.